Have a feature idea you'd love to see implemented?
Let us know!
XGN Exagen Inc
Price (delayed)
$2.72
Market cap
$47.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.97
Enterprise value
$46.33M
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and
Highlights
The EPS has soared by 52% YoY and by 11% from the previous quarter
The company's net income has surged by 51% YoY and by 11% QoQ
XGN's debt is down by 3.8% year-on-year but it is up by 2.1% since the previous quarter
Exagen's equity has decreased by 45% YoY and by 12% from the previous quarter
XGN's quick ratio is down by 31% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of XGN
Market
Valuations
Earnings
Shares outstanding
17.39M
Market cap
$47.29M
Enterprise value
$46.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.69
Price to sales (P/S)
0.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.82
Revenue
$56.66M
EBIT
-$15.05M
EBITDA
-$12.15M
Free cash flow
-$6.33M
Per share
Balance sheet
Liquidity
EPS
-$0.97
Free cash flow per share
-$0.35
Book value per share
$1.01
Revenue per share
$3.12
TBVPS
$2.71
Total assets
$49.31M
Total liabilities
$31.72M
Debt
$23.52M
Equity
$17.59M
Working capital
$31.35M
Debt to equity
1.34
Current ratio
4.32
Quick ratio
3.83
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
-21.4%
Gross margin
59.1%
Net margin
-30.6%
Operating margin
-27.9%
Return on assets
-31.8%
Return on equity
-78.9%
Return on invested capital
-38.8%
Return on capital employed
-37.8%
Return on sales
-26.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XGN stock price
How has the Exagen stock price performed over time
Intraday
-1.09%
1 week
-5.23%
1 month
-11.69%
1 year
33.33%
YTD
36.68%
QTD
-11.97%
Financial performance
How have Exagen's revenue and profit performed over time
Revenue
$56.66M
Gross profit
$33.51M
Operating income
-$15.81M
Net income
-$17.31M
Gross margin
59.1%
Net margin
-30.6%
The operating margin has soared by 58% YoY and by 14% from the previous quarter
The operating income has soared by 55% year-on-year and by 13% since the previous quarter
XGN's net margin has soared by 54% year-on-year and by 12% since the previous quarter
The company's net income has surged by 51% YoY and by 11% QoQ
Growth
What is Exagen's growth rate over time
Valuation
What is Exagen stock price valuation
P/E
N/A
P/B
2.69
P/S
0.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.82
The EPS has soared by 52% YoY and by 11% from the previous quarter
XGN's price to book (P/B) is 79% higher than its last 4 quarters average of 1.5 and 17% higher than its 5-year quarterly average of 2.3
Exagen's equity has decreased by 45% YoY and by 12% from the previous quarter
The P/S is 67% less than the 5-year quarterly average of 2.6 but 45% more than the last 4 quarters average of 0.6
Exagen's revenue has increased by 7% YoY
Efficiency
How efficient is Exagen business performance
The ROS has soared by 57% YoY and by 13% from the previous quarter
The company's return on invested capital rose by 41% YoY and by 7% QoQ
Exagen's return on assets has increased by 25% YoY and by 4.5% QoQ
The company's return on equity rose by 7% YoY but it fell by 4% QoQ
Dividends
What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XGN.
Financial health
How did Exagen financials performed over time
The total assets is 55% greater than the total liabilities
XGN's quick ratio is down by 31% year-on-year and by 12% since the previous quarter
Exagen's current ratio has decreased by 28% YoY and by 11% from the previous quarter
XGN's debt is 34% greater than its equity
The debt to equity has soared by 74% YoY and by 17% from the previous quarter
Exagen's equity has decreased by 45% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.